Efficacy and Safety of a Single Dose of Casirivimab and Imdevimab for the Prevention of COVID-19 Over an 8-Month Period
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Infectious Diseases
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial
Lancet Infect Dis 2022 Oct 01;22(10)1444-1454, GA Herman, MP O'Brien, E Forleo-Neto, N Sarkar, F Isa, P Hou, KC Chan, KJ Bar, RV Barnabas, DH Barouch, MS Cohen, CB Hurt, DR Burwen, MA Marovich, BJ Musser, JD Davis, KC Turner, A Mahmood, AT Hooper, JD Hamilton, J Parrino, D Subramaniam, A Baum, CA Kyratsous, AT DiCioccio, N Stahl, N Braunstein, GD Yancopoulos, DM WeinreichFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.